BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30923094)

  • 1. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.
    Minnema MC; Nasserinejad K; Hazenberg B; Hegenbart U; Vlummens P; Ypma PF; Kröger N; Wu KL; Kersten MJ; Schaafsma MR; Croockewit S; de Waal E; Zweegman S; Tick L; Broijl A; Koene H; Bos G; Sonneveld P; Schönland S
    Haematologica; 2019 Nov; 104(11):2274-2282. PubMed ID: 30923094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
    Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
    BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
    Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.
    Landau H; Lahoud O; Devlin S; Lendvai N; Chung DJ; Dogan A; Landgren CO; Giralt S; Hassoun H
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):204-208. PubMed ID: 31446197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
    Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
    Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferred autologous stem cell transplantation in systemic AL amyloidosis.
    Manwani R; Hegenbart U; Mahmood S; Sachchithanantham S; Kyriakou C; Yong K; Popat R; Rabin N; Whelan C; Dittrich T; Kimmich C; Hawkins P; Schönland S; Wechalekar A
    Blood Cancer J; 2018 Nov; 8(11):101. PubMed ID: 30397193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
    Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
    Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.
    Sharpley FA; Manwani R; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Martinez De Azcona Naharro A; Gillmore JD; Whelan CJ; Fontana M; Cohen O; Hawkins PN; Wechalekar AD
    Eur J Haematol; 2021 Apr; 106(4):537-545. PubMed ID: 33460466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
    Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
    Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
    Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
    Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Kumar SK; Leung N; Lust J; Rajkumar SV; Russell SJ; Suman VJ; Le-Rademacher JG; Hogan WJ
    Cancer; 2016 Jul; 122(14):2197-205. PubMed ID: 27142462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
    Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.